Gastroenterologist
Lifespan Physician Group
Providence, Rhode Island
The focus of Dr. Kelly’s research and clinical practice is Clostridioides difficile infection (CDI) and fecal microbiota transplantation (FMT). She was the principal investigator for the first placebo-controlled trial of FMT for treatment of recurrent CDI and one of the first investigators to sponsor of an investigational new drug application for this treatment with the FDA. She subsequently served on working graoups around regulatory issues related to microbiota based therapies. Dr. Kelly has been involved in industry-funded trials of live biotherapeutic products and collaborated on studies looking at FMT in patients with inflammatory bowel disease. She is interested in the long-term effects around manipulation of gut microbiota and is a PI for the NIH-funded FMT National Patient Registry which will answer important questions around real-world effectiveness and safety. In addition to coauthoring current FMT guidelines and participating in drafting the European Consensus Conference on FMT in Clinical Practice, she was the lead author for the recently published American College of Gastroenterology 2021 CDI treatment guidelines. Dr. Kelly is a Fellow in the ACG and is a Fellow and past member of the scientific advisory board for Gut Microbiome Research and Education of the American Gastroenterological Association .
Disclosure information not submitted.
Tuesday, October 18, 2022
1:30 PM – 2:30 PM ET